Predicting the future: Socio-economic trends in Hodgkin versus non-Hodgkin lymphoma survival outcomes.

e19036 Background: Lymphoma, categorized into Hodgkin (HL) and Non-Hodgkin (NHL), is the most common hematological malignancy worldwide. NHL is the eighth most common malignancy in the US and accounts for 3.3% of all cancer related deaths. HL is a relatively rare entity with 88.9% 5-Year Relative Survival Rate in the US. Socio-demographic factors play a pivotal role in the incidence and survival outcomes. This study aims to compare the evolving epidemiological landscape of HL versus NHL in different socio-demographic groups. Methods: Incidence and mortality data for HL and NHL across 185 countries were obtained from the GLOBOCAN database which is publicly available. An explorative analysis was performed to assess temporal changes in these rates from 2022 to 2040. The incidence and mortality rates were stratified and compared across socio-economic groups to identify potential disparities and trends. Results: From 2022 to 2040, the global incidence of HL is predicted to increase by 7.3% in age group 0-39 years and by 43.3% in 40-85+ years, with an increase of 68.2% in mortality amongst 60+ age group. In contrast, the incidence of NHL is expected to rise by 47.5%, with a 53.3% rise in individuals aged 40+ and increase in mortality by 72.5%. The regional variations highlight significant disparities. For HL, the WHO African region (AFRO) is predicted to experience the highest increase in incidence (66.4%), followed by the Eastern Mediterranean region (EMRO) (47.1%). Mortality trends mirror this pattern, with the highest rise in the AFRO (69.8%) and the lowest in the EURO (19.7%). Similarly, NHL shows the most substantial increase in the AFRO (69.8%). Interestingly, mortality rates are expected to increase the most in EMRO (73.9%) and AFRO (69.8%). With income levels, HL incidence is projected to rise most in low-income countries (67.1%) and the lowest in high-income (6.5%). Mortality changes follow a similar trend, with the highest increase in low-income (68.1%) and the lowest in high-income regions (31.3%). For NHL, expected increase of 71.4% in low-income and 27.6% in high-income countries. Mortality changes peak in low-income regions (71.4%). With respect to the Human Development Index (HDI), low-HDI countries are expected to see the highest increase in HL incidence (64.5%) and mortality (65.8%). For NHL, low-HDI countries similarly exhibit the largest proportional rise in incidence (69.1%) and mortality (71.5%). Conclusions: The projected increases in incidence and mortality highlight significant global disparities amongst population groups based on age, region, and socioeconomic factors. Low-income and low-HDI regions face the steepest challenges, both in relation to incidence and mortality, contributing to disproportionately high mortality rates. Addressing these gaps requires global efforts to ensure equitable access to innovative treatments.